WO1991007408A1 - Imidazoquinoxaline compounds, their preparation and use - Google Patents

Imidazoquinoxaline compounds, their preparation and use Download PDF

Info

Publication number
WO1991007408A1
WO1991007408A1 PCT/DK1990/000303 DK9000303W WO9107408A1 WO 1991007408 A1 WO1991007408 A1 WO 1991007408A1 DK 9000303 W DK9000303 W DK 9000303W WO 9107408 A1 WO9107408 A1 WO 9107408A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
general formula
alkyl
set forth
forth above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK1990/000303
Other languages
French (fr)
Inventor
Frank Wätjen
Holger Claus Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to DE69009493T priority Critical patent/DE69009493T2/en
Priority to KR1019920701199A priority patent/KR920703593A/en
Priority to EP90917143A priority patent/EP0502885B1/en
Publication of WO1991007408A1 publication Critical patent/WO1991007408A1/en
Priority to NO921886A priority patent/NO300064B1/en
Priority to FI922269A priority patent/FI97228C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the present invention relates to therapeutically active imidazoquinoxaline compounds, a method of preparing the same, pharmaceutical compositions comprising the compounds, and to methods of treating therewith.
  • the novel compounds are useful in psychopharmaceutical applications, e.g., in the treatment of central nervous system ailments, for example, as anticonvulsants or anxiolytics.
  • R 1 and R2 independently are hydrogen, straight
  • R is hy ⁇ drogen, straight or branched C 1 _ ⁇ -alkyl, straight or branched C 2 _ ⁇ - alkenyl, or aralkyl or aroylalkyl which may optionally be substituted with halogen or C 1 _,- alkoxy;
  • R 4 and R5 independently are hydrogen, halogen,
  • the invention also relates to a method of preparing the above mentioned compounds. This method comprises:
  • R 3, R4 and R5 have the meanings set forth above, with a compound having the general formula III
  • R 1, R3, R4 and R5 have the meanings set forth above, or
  • R , R R 3, R4 and R5 have the meanings set forth above.
  • the leaving group, Y may be any suitable leaving group and, for example, those disclosed in U.S. Patents 4,031,079 or 4,359,420, for example, halogen, alkyl- thio, e.g., methylthio, aralkylthio, N-nitrosoalkyl- amino, alkoxy, mercapto, -OP(0)(OR) 2 wherein R is lower-alkyl or -OP(0)(NR'R * * ) 2 wherein R * and R * * each represents lower- alkyl or phenyl, or together with the nitrogen atom to which they are attached represent a heterocyclic radical such as morpholino, pyrrolidino, piperidino, or methylpiperazino.
  • halogen alkyl- thio, e.g., methylthio, aralkylthio, N-nitrosoalkyl- amino, alkoxy, mercapto, -OP(0)(OR) 2 wherein R is
  • the reaction is pre ⁇ ferably carried out under alkaline conditions, i.e., in the presence of a base, and among bases alkali metal, e.g., potassium or sodium, alkoxides or hydrides are preferred.
  • the reaction is preferably conducted in the presence of an organic solvent which is nonreactive with the reactants and products of reaction under the conditions of reaction, especially an anhydrous sol ⁇ vent and preferably an anhydrous aprotic solvent such as dimethylformamide (DMF) or the like.
  • the temperature range employed may be any range suitable for the reac ⁇ tion to proceed at a reasonable rate and without undue delay or decomposition and a range from a minus forty (-40) degrees Celsius to about room temperature is accordingly usually particularly suitable.
  • the starting materials may be prepared from commer ⁇ cially available organic compounds and by using well known synthetic methods.
  • the pharmaceutical properties of the compounds of the invention can be illustrated by determining their capability for displacing radioactive labelled fluni- trazepam from benzodiazepine receptors.
  • the displacement activity of the compounds of the invention may be found by determining the EDj- n value.
  • the ED J - value represents the dose (mg/kg) of a test substance which causes the specific binding of fluni- trazepam to benzodiazepine receptors in a living brain to be reduced to 50% of the control value.
  • H-flunitraze- 3 pam H-FNM
  • H-FNM H-flunitraze- 3 pam
  • H-FNM can be partly or completely prevented by simul ⁇ taneous or prior administration of pharmacologically active benzodiazepines and by some benzodiazepine-like agents (Chang and Snyder, Eur.J. Pharmacol. 48, 212-218 (1978)).
  • Test procedure Suspensions of test substances (2 mg/- ml) are prepared in 5% Duphasol-X (TM Duphar, castor oil- ethylene oxide derivative for emulsifying and solubilizing oil and other water-insoluble substances ) by sonification for 10 min using a Branson B15 microtip ultrasonifier (setting 7). Groups of three mice (female, NMR, 18-22 grams) are injected with the test substance at 100 mg/kg intraperitoneally. Fifteen minutes after test substance administration the mice are challenged with 4 ⁇ Ci intravenously of H-FNM (70-90 Ci/mole) in
  • H-FNM administration mice are sacrificed by decapita ⁇ tion, the forebrains rapidly excised (within 30 sec) and homogenized in 12 ml of icecold 25 mM KH 2 P0,, pH 7.1, using an Ultra-Turrax homogenizer fitted with an N 10 shaft. Two aliquots of 1 ml are immediately fil ⁇ tered through Whatman GF/C glassfibre filters and wash ⁇ ed with 2 x 5 ml of the above mentioned buffer. The amounts of radioactivity on the filters are determined by conventional scintillation counting. One group of untreated mice serves as control. One to three mice are injected with 25 ⁇ g/kg clonazepam i.p. 30 minutes
  • test substances are administered in doses, which are factors of 3.16 times lower than 100 mg/kg.
  • the ED,- n for a test sub- stance is defined as that dose which inhibits 50% of 3 specific H-FNM binding.
  • Specific binding is the amount of binding in controls minus the amount binding in clonazepam- treated mice.
  • the ED 5 _ value is determined from dose re ⁇ sponse curves. If only one dose of test substance is administered the ED_ 0 value is calculated as follows, provided that the inhibition of specific binding is within the range of 25-75%:
  • the compound of the invention together with a con- ventional adjuvant, carrier, or diluent, and if desired in the form of a pharmaceutically-acceptable acid addi ⁇ tion salt thereof, may be placed into the form of phar ⁇ maceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppo ⁇ sitories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or with ⁇ out additional active compounds or principles, and such unit dosage forms may contain any suitable effective central nervous system ailment alleviating amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • Tablets containing one (1) milligram of active ingredient or, more broad ⁇ ly, one (1) to thirty (30) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of this invention can thus be used for the formulation of pharmaceutical preparations, e.g., for oral and parenteral administration to mammals in ⁇ cluding humans, in accordance with conventional methods of galenic pharmacy.
  • excipients are such pharmaceutically accept ⁇ able organic or inorganic carrier substances suitable for parenteral or oral application which do not delet ⁇ eriously react with the active compound.
  • Such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatin, lactose, amylose, magnesium ste- arate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the pharmaceutical preparations can be sterilized and mixed, if desired, with auxilliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compound.
  • auxilliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compound.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Ampoules are convenient unit dosage forms.
  • tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or po ⁇ tato starch.
  • a syrup, elixir or like can be used when a sweetened vehicle can be employed.
  • the compounds of the invention are dispensed in unit dosage form comprising 0.05-100 mg in a pharmaceutically-acceptable carrier per unit dosage.
  • a typical tablet which may be prepared by conventional tabletting techniques contains:
  • the compounds of the invention are extremely useful in the treatment of central nervous system ailments or disorders, when administered in an amount effective for the alleviation, amelioration, or elimination thereof.
  • the important CNS activity of the compounds of the invention includes both anticonvulsant and anxiolytic activities along with a low toxicity, together presenting a most favorable therapeutic index.
  • the compounds of the invention may accordingly be ad- ministered to a subject, e.g., a living animal or a human body, in need of the same for the treatment, alleviation, amelioration, or elimination of an indi ⁇ cation, associated with the central nervous system and the socalled benzodiazepin receptors, which requires such psychopharmaceutical treatment, e.g., especially convulsion and/or anxiety states, if desired in the form of a pharmaceuticallyacceptable acid addition salt thereof (such as the hydrobromide, hydrochloride, or sulfate, in any event prepared in the usual or conven ⁇ tional manner, e.g., evaporation to dryness of the free base in solution together with the acid), ordina- rily concurrently, simultaneously, or together with a pharmaceutically-acceptable carrier or diluent, espe ⁇ cially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or paren ⁇ teral (including subcutaneous) route, in
  • Suitable dosage ranges are 1-200 milligrams daily, 1-100 milligrams daily, and especially 1-30 milligrams daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

New imidazoquinoxaline compounds having general formula (I), wherein Q is (a), wherein R?1 and R?2 independently are hydrogen, straight or branched C1-6?-alkyl, or C3-7?-cycloalkyl; R?3 is hydrogen, straight or branched C1-6?-alkyl, straight or branched C2-6?-alkenyl, or aralkyl or aroylalkyl which may optionally be substituted with halogen or C1-6?-alkoxy; R?4 and R?5 independently are hydrogen, halogen, C1-6?-alkyl or trifluoromethyl. The compounds are useful in phychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics and in improving the cognitive function of the brain of mammals.

Description

IMIDAZOQUI OXALINE COMPOUNDS, THEIR PREPARATION AND USE
The present invention relates to therapeutically active imidazoquinoxaline compounds, a method of preparing the same, pharmaceutical compositions comprising the compounds, and to methods of treating therewith. The novel compounds are useful in psychopharmaceutical applications, e.g., in the treatment of central nervous system ailments, for example, as anticonvulsants or anxiolytics.
It is well known (Squires, R.F. and Braestrup, C. in Nature (London) 266 (1977) 732-734) that specific sites in the central nervous systems of vertebrates exhibit a high specific affinity for binding 1,4- and 1,5- benzodiazepines. These sites are called benzodiazepine receptors.
It has now been found that members of a novel group of imidazoquinoxaline compounds have strong affinity for the benzodiazepine receptors which make them useful in psychopharmaceutical preparations.
Accordingly, it is an object of the invention to pro- vide such novel imidazoquinoxaline compounds.
The imidazoquinoxaline compounds having the general formula I
Figure imgf000004_0001
wherein
0
Q is - C - CH - C RJ
Figure imgf000004_0002
wherein R 1 and R2 independently are hydrogen, straight
3 or branched C. _fi-alkyl, or C, 7-cycloalkyl; R is hy¬ drogen, straight or branched C1_β-alkyl, straight or branched C2_β- alkenyl, or aralkyl or aroylalkyl which may optionally be substituted with halogen or C1_,- alkoxy; R 4 and R5 independently are hydrogen, halogen,
C, .--alkyl or trifluoromethyl.
The invention also relates to a method of preparing the above mentioned compounds. This method comprises:
a) reacting a reactive derivative of a compound having the general formula II
Figure imgf000004_0003
wherein R 3, R4 and R5 have the meanings set forth above, with a compound having the general formula III
CH„ - C - R (III)
wherein R has the meaning set forth above, to form a compound of the general formula IV
Figure imgf000005_0001
wherein R 1, R3, R4 and R5 have the meanings set forth above, or
b) alkylating a compound having the general formula IV
Figure imgf000005_0002
wherein R 1, R3, R4 and R5 have the meanings set forth above, with an alkyl halide to form a compound of the general formula I
Figure imgf000006_0001
wherein R , R R 3, R4 and R5 have the meanings set forth above.
The leaving group, Y, may be any suitable leaving group and, for example, those disclosed in U.S. Patents 4,031,079 or 4,359,420, for example, halogen, alkyl- thio, e.g., methylthio, aralkylthio, N-nitrosoalkyl- amino, alkoxy, mercapto, -OP(0)(OR)2 wherein R is lower-alkyl or -OP(0)(NR'R* * )2 wherein R* and R* * each represents lower- alkyl or phenyl, or together with the nitrogen atom to which they are attached represent a heterocyclic radical such as morpholino, pyrrolidino, piperidino, or methylpiperazino. The reaction is pre¬ ferably carried out under alkaline conditions, i.e., in the presence of a base, and among bases alkali metal, e.g., potassium or sodium, alkoxides or hydrides are preferred. The reaction is preferably conducted in the presence of an organic solvent which is nonreactive with the reactants and products of reaction under the conditions of reaction, especially an anhydrous sol¬ vent and preferably an anhydrous aprotic solvent such as dimethylformamide (DMF) or the like. The temperature range employed may be any range suitable for the reac¬ tion to proceed at a reasonable rate and without undue delay or decomposition and a range from a minus forty (-40) degrees Celsius to about room temperature is accordingly usually particularly suitable. The starting materials may be prepared from commer¬ cially available organic compounds and by using well known synthetic methods.
The pharmaceutical properties of the compounds of the invention can be illustrated by determining their capability for displacing radioactive labelled fluni- trazepam from benzodiazepine receptors.
The displacement activity of the compounds of the invention may be found by determining the EDj-n value. The EDJ- value represents the dose (mg/kg) of a test substance which causes the specific binding of fluni- trazepam to benzodiazepine receptors in a living brain to be reduced to 50% of the control value.
Such an in vivo test is carried out as follows:
3 Principle. Twenty minutes after a dose of H-flunitraze- 3 pam ( H-FNM) (200 μCi/kg, i.v.) the amount of specific 3 H-FNM binding to brain benzodiazepine receptors has reached its maximal value. This specific binding of 3
H-FNM can be partly or completely prevented by simul¬ taneous or prior administration of pharmacologically active benzodiazepines and by some benzodiazepine-like agents (Chang and Snyder, Eur.J. Pharmacol. 48, 212-218 (1978)).
Test procedure. Suspensions of test substances (2 mg/- ml) are prepared in 5% Duphasol-X (TM Duphar, castor oil- ethylene oxide derivative for emulsifying and solubilizing oil and other water-insoluble substances ) by sonification for 10 min using a Branson B15 microtip ultrasonifier (setting 7). Groups of three mice (female, NMR, 18-22 grams) are injected with the test substance at 100 mg/kg intraperitoneally. Fifteen minutes after test substance administration the mice are challenged with 4 μCi intravenously of H-FNM (70-90 Ci/mole) in
200 μl physiological saline. Twenty minutes after 3
H-FNM administration mice are sacrificed by decapita¬ tion, the forebrains rapidly excised (within 30 sec) and homogenized in 12 ml of icecold 25 mM KH2P0,, pH 7.1, using an Ultra-Turrax homogenizer fitted with an N 10 shaft. Two aliquots of 1 ml are immediately fil¬ tered through Whatman GF/C glassfibre filters and wash¬ ed with 2 x 5 ml of the above mentioned buffer. The amounts of radioactivity on the filters are determined by conventional scintillation counting. One group of untreated mice serves as control. One to three mice are injected with 25 μg/kg clonazepam i.p. 30 minutes
3 before H-FNM to determine the amount of non- specific 3 H-FNM binding, which should be between 8-15% of total binding. When doses of 100 mg/kg inhibit more than 50%
3 of specific H-flunitrazepam binding; test substances are administered in doses, which are factors of 3.16 times lower than 100 mg/kg. The ED,-n for a test sub- stance is defined as that dose which inhibits 50% of 3 specific H-FNM binding. Specific binding is the amount of binding in controls minus the amount binding in clonazepam- treated mice.
Results. The ED5_ value is determined from dose re¬ sponse curves. If only one dose of test substance is administered the ED_0 value is calculated as follows, provided that the inhibition of specific binding is within the range of 25-75%:
ED 5,.0,. = (administered dose) x mg/kg
— - 1 where C is specific binding in controls and C is specific binding in mice treated with test substance.
Test results obtained by testing some compounds of the invention will appear from the following table I.
TABLE 1.
Compound ED50 (mg/kg)
Compound 2 1.5 Compound 4 1.4 Compound 6 2.5
The compound of the invention, together with a con- ventional adjuvant, carrier, or diluent, and if desired in the form of a pharmaceutically-acceptable acid addi¬ tion salt thereof, may be placed into the form of phar¬ maceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppo¬ sitories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or with¬ out additional active compounds or principles, and such unit dosage forms may contain any suitable effective central nervous system ailment alleviating amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing one (1) milligram of active ingredient or, more broad¬ ly, one (1) to thirty (30) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
The compounds of this invention can thus be used for the formulation of pharmaceutical preparations, e.g., for oral and parenteral administration to mammals in¬ cluding humans, in accordance with conventional methods of galenic pharmacy.
Conventional excipients are such pharmaceutically accept¬ able organic or inorganic carrier substances suitable for parenteral or oral application which do not delet¬ eriously react with the active compound.
Examples of such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatin, lactose, amylose, magnesium ste- arate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
The pharmaceutical preparations can be sterilized and mixed, if desired, with auxilliary agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compound.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Ampoules are convenient unit dosage forms.
For oral application, particularly suitable are tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or po¬ tato starch. A syrup, elixir or like can be used when a sweetened vehicle can be employed. Generally, as to broader ranges, the compounds of the invention are dispensed in unit dosage form comprising 0.05-100 mg in a pharmaceutically-acceptable carrier per unit dosage.
A typical tablet which may be prepared by conventional tabletting techniques contains:
Active compound 1.0 mg
Lactosum 67.8 mg Ph.Eur.
Avicel 31.4 mg
Amberlite® IRP 88 1.0 mg
Magnesii stearas 0.25 mg Ph.Eur.
Due to their high degree of affinity for the benzodia- zepin receptors, the compounds of the invention are extremely useful in the treatment of central nervous system ailments or disorders, when administered in an amount effective for the alleviation, amelioration, or elimination thereof. The important CNS activity of the compounds of the invention includes both anticonvulsant and anxiolytic activities along with a low toxicity, together presenting a most favorable therapeutic index. The compounds of the invention may accordingly be ad- ministered to a subject, e.g., a living animal or a human body, in need of the same for the treatment, alleviation, amelioration, or elimination of an indi¬ cation, associated with the central nervous system and the socalled benzodiazepin receptors, which requires such psychopharmaceutical treatment, e.g., especially convulsion and/or anxiety states, if desired in the form of a pharmaceuticallyacceptable acid addition salt thereof (such as the hydrobromide, hydrochloride, or sulfate, in any event prepared in the usual or conven¬ tional manner, e.g., evaporation to dryness of the free base in solution together with the acid), ordina- rily concurrently, simultaneously, or together with a pharmaceutically-acceptable carrier or diluent, espe¬ cially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or paren¬ teral (including subcutaneous) route, in an effective psychopharmaceutical central nervous system ailment alleviating amount, e.g., an anticonvulsant and/or anxiolytic amount, and in any event an amount which is effective for the alleviation of such a central nervous system ailment due to their benzodiazepine receptor affinity. Suitable dosage ranges are 1-200 milligrams daily, 1-100 milligrams daily, and especially 1-30 milligrams daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.
The invention will now be described in further detail with reference to the following examples:
EXAMPLE 1
5-tert-butyl-4,5-dihydro-3-(4,4-dimethyl-l,3-dioxopen- tyl)-4-oxo-imidazo[l, 5-a]quinoxaline
To a stirred mixture of ethyl 5-tert-butyl-4, 5-dihydro- 4-oxo-imidazo[l,5-a]quinoxaline-3-carboxylate (1.6 g, 5 mmol) and pinacolone (1.25 ml, 10 mmbl) in dry tetra- hydrofuran (THF) (30 ml) was added sodium hydride (200 mg, 80% in mineral oil, 6.9 mmol). The mixture was brought to reflux for 2 h, then cooled to room tempe¬ rature and neutralized with acetic acid. After evapo¬ ration of the solvent the residue was partitioned be¬ tween sat. aqueous NaHC0„ (10 ml) and methylene chloride (30 ml) . The organic phase was dried over Na2S0. and evaporated to give the title compound as yellow cry¬ stals. M.p. 190-191 °C. (Compound 1).
From the appropriate methyl ketones and ethyl imidazo- quinoxalinecarboxylates the following 1,3-diketones were prepared:
3-(3-cyclopropyl-l,3-dioxopropyl)-4, 5-dihydro-5-iso- propyl-4-oxo-imidazo[l, 5-a]quinoxaline, m.p. 210-212 C from reaction between cyclopropyl methyl ketone and ethyl 4, 5-dihydro-5-isopropyl-4-oxo-imidazo[l, 5-a]qui- noxaline-3-carboxylate. (Compound 2).
6-chloro-3-(3-cyclopropyl-l,3-dioxopropyl)-4, 5-dihydro- 5-methyl-4-oxo-imidazo[l,5-a]quinoxaline. M.p. 189-
190 C from reaction between cyclopropyl methyl ketone and ethyl 6-chloro-4,5-dihydro-5-methyl-4-oxo-imidazo- [1, 5-a]quinoxaline-3-carboxylate. (Compound 3) .
4,5-dihydro-5-isopropyl-4-oxo-3-( 1,3-dioxobutyl)- imidazo[l, 5-a]quinoxaline, m.p. 216-218 C from reac¬ tion between acetone and ethyl 4, 5-dihydro-5-isopro- pyl-4-oxo-imidazo[1, 5-a]quinoxaline-3-carboxylate. (Compound 4) .
5-tert-butyl-4, 5-dihydro-4-oxo-3-(1,3-dioxobutyl)- imidazo[l, 5-a]quinoxaline, m.p. 175-177 C from reac¬ tion between acetone and ethyl 5-tert-butyl-4, 5- dihydro-4-oxo-imidazo[1, 5-a]quinoxaline-3-carboxylate. (Compound 5).
5-tert-butyl-3-(3-cyclopropyl-l,3-dioxopropyl)-4, 5- dihydro-4-oxo-imidazo[l,5-a]quinoxaline, m.p. 175- 178 C from reaction between cyclopropyl methyl ketone and ethyl 5-tert-butyl-4,5-dihydro-4-oxo-imidazo- [1,5-a]quinoxaline-3-carboxylate. (Compound 6).
EXAMPLE 2
3-(3-cyclopropyl-2-methyl-l,3-dioxopropyl)-4,5- dihydro-5-isopropyl-4-oxo-imidazo[1,5-a]quinoxaline
Sodium hydride (0.8 g, 60% in mineral oil) was added to a stirred solution of cyclopropyl methyl ketone (1.12 ml, 12 mmol) in dry THF (40 ml). Then ethyl 4,5- dihydro-5-isopropyl-4-oxo-imidazo[l,5-a]quinoxaline-
3-carboxylate (3 g, 10 mmol) was added and the mixture was heated at reflux for 30 min. The resulting solution was cooled to room temperature and an excess of methyl iodide (1.4 ml) was added. After stirring overnight the mixture was neutralized with acetic acid and the solv¬ ent was evaporated. The residue was triturated with a mixture of ether and water and the precipitate was collected by filtration, rinsed with saturated aqueous NaHC03, recrystallized from isopropyl alcohol and finally purified by column chromatography (Si02/dichlor- omethane-acetone 4:1), m.p. 167- 169°C. (Compound 7).

Claims

1. Imidazoquinoxaline compounds having the general formula I
Figure imgf000015_0001
wherein
Q is - C - CH - C - R
Figure imgf000015_0002
wherein R 1 and R2 independently are hydrogen, straight
3 or branched C. ,-alkyl, or C- 7-cycloalkyl; R is hy¬ drogen, straight or branched C._fi-alkyl, straight or branched C _fi-alkenyl, or aralkyl or aroylalkyl which may optionally be substituted with halogen or C. fi- alkoxy; R 4 and R5 independently are hydrogen, halogen,
C1_fi-alkyl or trifluoromethyl
2___ A compound which is 4,5-dihydro-5-isopropyl-4-oxo- 3-(1,3-dioxobutyl)-imidazo[1,5-a]quinoxaline
3. A compound which is 3-(3-cyclopropyl-l,3-dioxopro¬ pyl)-4,5-dihydro-5-isopropyl-4-oxo-imidazo[l,5-a]qui- noxaline
A compound which is 5-tert-butyl-3-(3-cyclopropyl- 1,3-dioxopropyl)-4,5-dihydro-4-oxo-imidazo[1,5-a]qui- noxaline
5. A method of preparing a compound according to claim 1, CHARACTERIZED in
a) reacting a reactive derivative of a compound having the general formula II
Figure imgf000016_0001
wherein R 3, R4, and R5 have the meanings set forth above, with a compound having the general formula III
CH-, - C - R (III)
wherein R has the meaning set forth above, to form a compound of the general formula IV
Figure imgf000016_0002
wherein R1, R3, R4 and R5 have the meanings set forth above, or
b) alkylating a compound having the general formula IV
Figure imgf000017_0001
wherein R 1, R3, R4 and R5 have the meanings set forth above, with an alkyl halide to form a compound of the general formula I
Figure imgf000017_0002
wherein R 1, R2, R3, R4 and R5 have the meanings set forth above.
6. A pharmacaeutical composition suitable for use in the treatment of a central nervous system ailment com¬ prising an amount of a compound of claim 1 which is effective for the alleviation of such disorder together with a pharmaceutically-acceptable carrier or diluent.
7. A pharmaceutical composition according to claim 6 wherein it is in the form af an oral dosage unit con- taining 1-100 mg of the active compound.
8. A method of treating a central nervous system ail¬ ment in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound of Claim 1 which is effective for the alle¬ viation of such ailment.
9. A method of treating a central nervous system ail- ment in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound of Claim 1 which is effective for the alle¬ viation of such ailment in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically acceptable carrier or diluent.
PCT/DK1990/000303 1989-11-22 1990-11-22 Imidazoquinoxaline compounds, their preparation and use Ceased WO1991007408A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69009493T DE69009493T2 (en) 1989-11-22 1990-11-22 IMIDAZOQUINOXALINE COMPOUNDS, THEIR PRODUCTION AND USE.
KR1019920701199A KR920703593A (en) 1989-11-22 1990-11-22 Imidazoquinoxaline compound, preparation method and use thereof
EP90917143A EP0502885B1 (en) 1989-11-22 1990-11-22 Imidazoquinoxaline compounds, their preparation and use
NO921886A NO300064B1 (en) 1989-11-22 1992-05-13 Analogous Process for the Preparation of Therapeutically Active Imidazoquinoxaline Compounds
FI922269A FI97228C (en) 1989-11-22 1992-05-19 Process for the preparation of novel therapeutically useful 4-oxo-imidazo / 1,5-a / quinoxaline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK588389A DK588389D0 (en) 1989-11-22 1989-11-22 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE
DK5883/89 1989-11-22

Publications (1)

Publication Number Publication Date
WO1991007408A1 true WO1991007408A1 (en) 1991-05-30

Family

ID=8145913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1990/000303 Ceased WO1991007408A1 (en) 1989-11-22 1990-11-22 Imidazoquinoxaline compounds, their preparation and use

Country Status (19)

Country Link
US (1) US5102885A (en)
EP (1) EP0502885B1 (en)
JP (1) JPH05503084A (en)
KR (1) KR920703593A (en)
AT (1) ATE106405T1 (en)
AU (1) AU645508B2 (en)
CA (1) CA2073046A1 (en)
DE (1) DE69009493T2 (en)
DK (2) DK588389D0 (en)
ES (1) ES2055454T3 (en)
FI (1) FI97228C (en)
HU (1) HUT63420A (en)
IE (1) IE69960B1 (en)
IL (1) IL96372A (en)
NO (1) NO300064B1 (en)
NZ (1) NZ236156A (en)
PT (1) PT95972B (en)
WO (1) WO1991007408A1 (en)
ZA (1) ZA909304B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722789A1 (en) * 1994-07-20 1996-01-26 Rhone Poulenc Rorer Sa IMIDAZO (1,2-A) INDENO (1,2-E) PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK588489D0 (en) * 1989-11-22 1989-11-22 Ferrosan As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225013A1 (en) * 1985-10-17 1987-06-10 A/S Ferrosan Heterocyclic compounds and their preparation and use
EP0283162A2 (en) * 1987-03-18 1988-09-21 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
EP0320136A2 (en) * 1987-12-08 1989-06-14 Novo Nordisk A/S Imidazoquinoxaline compounds and their preparation and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659329B1 (en) * 1990-03-09 1994-06-03 Adir NOVEL IMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225013A1 (en) * 1985-10-17 1987-06-10 A/S Ferrosan Heterocyclic compounds and their preparation and use
EP0283162A2 (en) * 1987-03-18 1988-09-21 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
EP0320136A2 (en) * 1987-12-08 1989-06-14 Novo Nordisk A/S Imidazoquinoxaline compounds and their preparation and use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722789A1 (en) * 1994-07-20 1996-01-26 Rhone Poulenc Rorer Sa IMIDAZO (1,2-A) INDENO (1,2-E) PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME
WO1996002544A1 (en) * 1994-07-20 1996-02-01 Rhone-Poulenc Rorer S.A. IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME

Also Published As

Publication number Publication date
KR920703593A (en) 1992-12-18
PT95972B (en) 1998-01-30
JPH05503084A (en) 1993-05-27
IL96372A0 (en) 1991-08-16
FI922269L (en) 1992-05-19
FI97228C (en) 1996-11-11
NZ236156A (en) 1993-01-27
NO300064B1 (en) 1997-04-01
DE69009493T2 (en) 1994-12-08
IE904157A1 (en) 1991-05-22
NO921886L (en) 1992-05-13
AU645508B2 (en) 1994-01-20
CA2073046A1 (en) 1991-05-23
ATE106405T1 (en) 1994-06-15
DE69009493D1 (en) 1994-07-07
PT95972A (en) 1991-09-13
IL96372A (en) 1994-10-21
DK588389D0 (en) 1989-11-22
US5102885A (en) 1992-04-07
EP0502885A1 (en) 1992-09-16
AU6742990A (en) 1991-06-13
DK0502885T3 (en) 1994-09-26
IE69960B1 (en) 1996-10-16
HU9201709D0 (en) 1992-09-28
ES2055454T3 (en) 1994-08-16
FI922269A0 (en) 1992-05-19
EP0502885B1 (en) 1994-06-01
ZA909304B (en) 1991-09-25
HUT63420A (en) 1993-08-30
FI97228B (en) 1996-07-31
NO921886D0 (en) 1992-05-13

Similar Documents

Publication Publication Date Title
US4774245A (en) Imidazoquinoxaline compounds
US5034530A (en) Imidazoquinoxaline compounds and their preparation and use
EP0241682B1 (en) Novel benzodiazepine derivatives and their preparation and use
US4999354A (en) Imidazoquinoxaline compounds and their preparation and use
AU673814B2 (en) Imidazoquinazoline compounds and their preparation and use
EP0226282B1 (en) Heterocyclic compounds and their preparation and use
EP0201678B1 (en) 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine, a process for its preparation and pharmaceutical compositions
US5075304A (en) Imidazoquinoxaline compounds and their preparation and use
AU645508B2 (en) Imidazoquinoxaline compounds, their preparation and use
EP0502038B1 (en) Imidazoquinoxaline compounds, their preparation and use
AU8063391A (en) Heterocyclic compounds and their preparation and use
EP0202441B1 (en) Oxadiazolylimidazobenzodiazepines, process for their preparation and pharmaceutical compositions
US4745112A (en) Oxadiazolylimidazobenzodiazepine, compositions, and method III
AU650733B2 (en) Tetracyclic imidazoquinazoline derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI HU JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2073046

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 922269

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1990917143

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990917143

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990917143

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 922269

Country of ref document: FI